FR2925333B1 - Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives - Google Patents

Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Info

Publication number
FR2925333B1
FR2925333B1 FR0759971A FR0759971A FR2925333B1 FR 2925333 B1 FR2925333 B1 FR 2925333B1 FR 0759971 A FR0759971 A FR 0759971A FR 0759971 A FR0759971 A FR 0759971A FR 2925333 B1 FR2925333 B1 FR 2925333B1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
active ingredient
digestive enzymes
protein active
protects digestive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0759971A
Other languages
English (en)
French (fr)
Other versions
FR2925333A1 (fr
Inventor
Farid Bennis
Jean Jacques Serrano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0759971A priority Critical patent/FR2925333B1/fr
Application filed by Individual filed Critical Individual
Priority to JP2010538869A priority patent/JP5676272B2/ja
Priority to BRPI0821373A priority patent/BRPI0821373B8/pt
Priority to HK11100516.2A priority patent/HK1146386B/xx
Priority to EP08867946.9A priority patent/EP2234598B1/fr
Priority to EA201070746A priority patent/EA023107B1/ru
Priority to MX2010006927A priority patent/MX2010006927A/es
Priority to PCT/FR2008/052357 priority patent/WO2009083686A1/fr
Priority to ES08867946T priority patent/ES3055634T3/es
Priority to AU2008345474A priority patent/AU2008345474B2/en
Priority to CA2709899A priority patent/CA2709899C/fr
Priority to CN200880125189XA priority patent/CN101917967B/zh
Priority to KR1020107013390A priority patent/KR101592609B1/ko
Priority to AP2010005298A priority patent/AP3573A/xx
Priority to KR1020157032578A priority patent/KR20150132887A/ko
Priority to US12/339,310 priority patent/US8309123B2/en
Priority to ARP080105568A priority patent/AR069847A1/es
Priority to TW097149879A priority patent/TWI461226B/zh
Publication of FR2925333A1 publication Critical patent/FR2925333A1/fr
Priority to IL206364A priority patent/IL206364A/en
Priority to TN2010000290A priority patent/TN2010000290A1/fr
Priority to MA32934A priority patent/MA31927B1/fr
Application granted granted Critical
Publication of FR2925333B1 publication Critical patent/FR2925333B1/fr
Priority to US13/674,578 priority patent/US20130090288A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0759971A 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives Active FR2925333B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
AP2010005298A AP3573A (en) 2007-12-19 2008-12-18 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
HK11100516.2A HK1146386B (en) 2007-12-19 2008-12-18 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
EP08867946.9A EP2234598B1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
EA201070746A EA023107B1 (ru) 2007-12-19 2008-12-18 Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами
MX2010006927A MX2010006927A (es) 2007-12-19 2008-12-18 Composiciones farmaceuticas que contienen al menos un ingrediente activo de proteina protegido contra las enzimas digestivas.
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
ES08867946T ES3055634T3 (en) 2007-12-19 2008-12-18 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
AU2008345474A AU2008345474B2 (en) 2007-12-19 2008-12-18 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
BRPI0821373A BRPI0821373B8 (pt) 2007-12-19 2008-12-18 composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas
CN200880125189XA CN101917967B (zh) 2007-12-19 2008-12-18 包含至少一种防消化酶消化的蛋白活性成分的药物组合物
KR1020107013390A KR101592609B1 (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물
JP2010538869A JP5676272B2 (ja) 2007-12-19 2008-12-18 消化酵素から保護される少なくとも１種のタンパク質活性成分を含む医薬組成物
KR1020157032578A KR20150132887A (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물
CA2709899A CA2709899C (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
ARP080105568A AR069847A1 (es) 2007-12-19 2008-12-19 Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas
TW097149879A TWI461226B (zh) 2007-12-19 2008-12-19 包含至少一種經保護而免受消化酶影響之蛋白質活性成份的醫藥組合物
US12/339,310 US8309123B2 (en) 2007-12-19 2008-12-19 Pharmaceutical compositions and methods for the oral delivery of insulin
IL206364A IL206364A (en) 2007-12-19 2010-06-14 Medicinal preparations containing at least one active protein component protected by digestive enzymes
TN2010000290A TN2010000290A1 (fr) 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
MA32934A MA31927B1 (fr) 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US13/674,578 US20130090288A1 (en) 2007-12-19 2012-11-12 Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (2)

Publication Number Publication Date
FR2925333A1 FR2925333A1 (fr) 2009-06-26
FR2925333B1 true FR2925333B1 (fr) 2012-04-13

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0759971A Active FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Country Status (19)

Country Link
US (1) US8309123B2 (enExample)
EP (1) EP2234598B1 (enExample)
JP (1) JP5676272B2 (enExample)
KR (2) KR101592609B1 (enExample)
CN (1) CN101917967B (enExample)
AP (1) AP3573A (enExample)
AR (1) AR069847A1 (enExample)
AU (1) AU2008345474B2 (enExample)
BR (1) BRPI0821373B8 (enExample)
CA (1) CA2709899C (enExample)
EA (1) EA023107B1 (enExample)
ES (1) ES3055634T3 (enExample)
FR (1) FR2925333B1 (enExample)
IL (1) IL206364A (enExample)
MA (1) MA31927B1 (enExample)
MX (1) MX2010006927A (enExample)
TN (1) TN2010000290A1 (enExample)
TW (1) TWI461226B (enExample)
WO (1) WO2009083686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
EP3215128B1 (en) 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2005113008A1 (en) * 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
PL1883394T3 (pl) 2005-05-23 2018-09-28 Sdg, Inc. Konstrukt lipidowy do dostarczania insuliny ssakowi
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20070134332A1 (en) * 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
WO2009083686A9 (fr) 2009-10-15
HK1146386A1 (en) 2011-06-03
US20090176691A1 (en) 2009-07-09
KR20100095449A (ko) 2010-08-30
ES3055634T3 (en) 2026-02-13
MA31927B1 (fr) 2010-12-01
EP2234598C0 (fr) 2025-11-19
AP2010005298A0 (en) 2010-06-30
CN101917967A (zh) 2010-12-15
BRPI0821373B1 (pt) 2020-04-22
JP5676272B2 (ja) 2015-02-25
FR2925333A1 (fr) 2009-06-26
US8309123B2 (en) 2012-11-13
TWI461226B (zh) 2014-11-21
EA201070746A1 (ru) 2011-02-28
EP2234598A1 (fr) 2010-10-06
IL206364A0 (en) 2010-12-30
CA2709899A1 (fr) 2009-07-09
TN2010000290A1 (fr) 2011-11-11
AU2008345474A1 (en) 2009-07-09
TW200940107A (en) 2009-10-01
IL206364A (en) 2016-12-29
CA2709899C (fr) 2018-01-16
BRPI0821373B8 (pt) 2021-05-25
EP2234598B1 (fr) 2025-11-19
AU2008345474B2 (en) 2014-07-31
EA023107B1 (ru) 2016-04-29
WO2009083686A1 (fr) 2009-07-09
KR101592609B1 (ko) 2016-02-05
BRPI0821373A2 (pt) 2015-06-16
AR069847A1 (es) 2010-02-24
MX2010006927A (es) 2010-12-06
JP2011506587A (ja) 2011-03-03
CN101917967B (zh) 2013-05-22
AP3573A (en) 2016-02-08
KR20150132887A (ko) 2015-11-26

Similar Documents

Publication Publication Date Title
FR2925333B1 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
WO2006135480A3 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA015464B9 (ru) Гербицидные составы с улучшенной эффективностью
DOP2011000074A (es) Compuestos y composiciones como inhibidores de proteina cinasa
MA35355B1 (fr) Formulations stabilisées contenant des anticorps anti-pcsk9
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
TW200735773A (en) Insecticidal compositions with improved activity
WO2008036932A3 (en) Compositions and methods comprising boswellia species
MA29413B1 (fr) Combinaisons de substances actives
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
UA107560C2 (uk) Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
FR2858556B1 (fr) Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
EA201071309A1 (ru) Твердая фармацевтическая композиция
BR0313570A (pt) Agente, e, uso do mesmo
MA31678B1 (fr) Composition therapeutique aromatisee a base d'argile
EP2053038A4 (en) AMINO ALCOHOL DERIVATIVE AND THESE IMMUNOSUP PRESSIVES CONTAINING ACTIVE INGREDIENTS
TW200738284A (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier
WO2004071402A3 (en) STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2006042625A3 (de) Zusammensetzungen mit inhibitoren der prostaglandin-und/oder leukotrien-synthese in kombination mit stimulatoren der freisetzung kutaren neuromediatoren
FR2881349B1 (fr) Nouvelle utilisation des galactomannanes en tant qu'agent actif en cosmetique.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19